Chris Limbert

Experience

• 

  PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania

  Jan 1969 - Jan 1978

  Senior Audit Manager and CPA

  A Global Big 4 Accounting Firm

• 

  Freeport-McMoRan Copper & Gold Inc.

  Jan 1978 - Jan 1982

  Vice President and Chief Financial Officer (Subsidiary)

  A Major World Class Natural Resources CompanySuccessor to AMAX, Inc., Greenwich ConnecticutAMAX Exploration, Inc., the exploration and development subsidiary of AMAX, Inc.Exploring and developing natural resource properties in seventeen countries on five continents.

• 

  BP

  Jan 1982 - Jan 1986

  Vice President and Chief Financial Officer (Subsidiary)

  formerly British Petroleum plcThe World's Third Largest Natural Resource Company.Amselco Natural Resources, Inc., Denver, ColoradoA wholly-owned subsidiary of BP plc in gold exploration, development, mining, and processing

• 

  Nestlé Waters North America

  Jan 1986 - Jan 1993

  Senior Manager Corporate Accounting

  $5.0 billion publicly owned bottled water and coffee manufacturer, distributor, and retailer, a subsidiary of Nestle S.A.

• 

  Clement Pappas & Co., Inc.

  Jan 1993 - Jan 1995

  Vice President and Chief Financial Officer

  $300 million privately owned brand and private label food manufacturer, shelf stable juice bottler, distributor, and retailer.

• 

  Clemens Markets, Inc.

  Jan 1995 - Jan 1999

  Chief Financial Officer

  $350 million privately-owned multi-location upscale food retailer and food service commissary with data base marketing system

• 

  Various Senior Financial and Operating Services' Engagments

  Jan 2000 - Jan 2004

  Chief Financial Officer

  o Chief Financial Officer - three Food Manufacturing and Distribution Companieso International Financial Reporting Standards ("IFRS") Implementation - Bracco S.p.A., a large Italian Pharmaceutical Company acquired EZ-EM, Inc., a U. S. NASDAQ-listed medical device manufacturer. Bracco required that EZ-EM convert from U. S. GAAP accounting to IFRS. Assisted Deloitte and PricewaterhouseCoopers with the implementation of IFRS.

• 

  Trenwick

  Jan 2005 - Jan 2006

  Senior Financial Consultant

  $2 billion private-equity owned, formerly a $5 billion publicly owned, financial services company in bankruptcy and liquidationo Assisted Trenwick's Controller before, during, and after the Chief Financial Officer's maternity leaveo Assisted with Financial Reporting using the Company's Oracle People Soft Accounting System.

• 

  PC Group, Inc.

  Jan 2006 - Jan 2007

  Chief Financial Officer

  formerly Langer, Inc.$80 million NASDAQ - listed ("pcgr") international marketer and manufacturer of medical devices and personal care productso CFO of acquisitive, complex, international Company with diverse cultures, systems, and controls.o Led preparation of fifteen (15) Securities Exchange Commission filings, including Forms 10-K, 10-Q, S-3s, and S-1 o Led accounting for acquisition of Twincraft, Inc., a $31 million manufacturer and marketer of soaps.o Led accounting for acquisition of Regal Medical Supply LLC., a $2 million medical device distributor. o Closed and accounted for $29 million private placement convertible subordinated note payable to fund growthPrepared SEC Form S-1 Registration Statement to register securities convertible under the above note payableo Led accounting for and execution of banking facility and $20 million lending facility with Wells Fargo Bank.o Led planning and implementation of Microsoft Dynamics SL consolidation and financial reporting system.o Implemented cost control and improved management of assets - cash, accounts receivable, inventory, PP&E.o Led monthly reviews with operating groups to monitor actual results versus plan and ensure policy compliance. o Planned and executed corporate financial and accounting function relocation to Manhattan from Long Island. Show less

• 

  PL Developments

  Jan 2008 - Jan 2009

  Chief Financial Officer

  Mid-sized privately held multi-location marketer and manufacturer of private label over-the-counter pharmaceutical products (aspirin, ibuprofen, sleep aids, cold and allergy remedies, etc.) for Wal-Mart, CVS, Walgreens, Costco, Rite Aid, Kroger, etc. o CFO of acquisitive, complex, multi-location Company with diverse cultures, systems, and controls reporting directly to Mitchell Singer, Chairman and Chief Executive Officer.o Improved business system structure and discipline.o Supervised a highly competent Controller, however CFO directly filled the role of Company Treasurer, with responsibility for banking relationships; cash planning, forecasting, and control; risk management, and tax planning and statutory reporting.o Along with the CEO ensured a positive compliant relationship, both orally and in formal contractual reporting, with JPMorgan Chase Bank.o Established a business operating plan and thirteen week and annual rolling cash forecasts.o Established timely and accurate financial reporting with management, bankers, and joint venture partners. o Developed a detailed multi-discipline one year Action Plan to establish functionality, systems, and people requirements for the next year. o Performed due diligence for a major acquisition. Show less

• 

  Connecticut Color

  Jan 2009 - Jan 2010

  Chief Accounting Officer

  Connecticut Color is a repidly growing commercial and direct mail printing company that continues to grow despite the challenging market for print materials in general. Worked side-by-side with the CFO during and subsequent to a major investment by a Private Equity Firm.o Performed Purchase Accounting and Asset Valuation subsequent to the Private Equity Firm major investment in the Company.o Revised the Company's Chart of Accounts in accordance with generally accepted accounting principles.o Assisted with Operating Plan and Financial Reporting.o Prepared for the Company's initial McGladrey audit examination. Show less

• 

  Kiss My Face Corp

  Jan 2010 - Jan 2011

  Chief Financial Officer

  Kiss My Face, LLC is a manufacturer, marketer, and distributor of organic and natural skin care and oral care products, including liquid and cake soaps, lotions, toothpaste, sun care lotions, lip, and hair care products.o Led the Company through transition subsequent to private equity firm investment.o Led the Company through its initial Grant Thornton LLP audit examination with no change.o Led the recording of the Company's acquisition purchase accounting.o Led the Company through its first operating plan, including periodic cash planning.o Identified and recognized substantial Allowance for Inventory Obsolescence thus improving future turnover and resultant improved profitability. Show less

• 

  NeoStem

  Jan 2010 - Jan 2010

  Information Systems Selection Consultant

  NeoStem, Inc.is a leader in the development and manufacture of stem cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. o Assisted the CFO and Controller with the development of a needs analysis for the selection of a consoldiation and financial reporting system required for this multi-entity multinational entity, including manufacturing entities in the Peoples Republic of China.o Assisted with the evaluation of proposals submitted by various software publishers of consoldiating and financial reporting systems. Show less

• 

  Aerie Pharmaceuticals, Inc.

  Jan 2011 - Jan 2012

  Chief Accounting Officer

  Aerie Pharmaceuticals, Inc. is focused on the development and commercialization of products for prevention and treatment of glaucoma and other eye diseases. A spinout from Duke University School of Medicine, its novel pro-drug technology facilitates development of NCEs for ophthalmology applications. Aerie's technology improves corneal penetration and duration of action. Ocular hypertension/glaucoma are significant underserved medical needs, and research suggests they are under diagnosed, under treated and their incidence/prevalence increases with age. Market focused on age-related macular degeneration (AMD) and other diseases of the "back of the eye" creating an opportunity for a new company focused on the front of the eye. Imminent patent expirations create an opportunity as well.. Development is in the clinical trials stage. Shareholders include five of the largest private equity firms in the United States led by the Texas Pacific Group. o Led the Company toward $60 million in initial public offering ("IPO") enabled by the completion of a multi-year PricewaterhouseCoopers LLP audit examination from the Company's inception in 2005 to 2012.o Accounted for very complex capital structure with multiple series of Preferred Stock and Mezzanine Debt.o Accounted for many Stock Option Contracts. Show less

• 

  Inuvo, Inc.

  Jan 2012 - Jan 2013

  Chief Accounting Officer

  Inuvo, Inc. is a NYSE-listed Internet Compnay that earns the bulk of its Revenues from providing services and internet applications to Google and Yahoo. Engaged by the Company's CFO during the maternity leave of the Controller. Managed the Company's Accounting Function including leading the finance and accounting department; drafting and filing the Company's Form 10-K with the SEC; leading a comprehensive Sarbanes-Oxley internal accounting control review, audit, and control remediation implementation; planning for and leading the independent accounting firm annual audit; and leading cash management, control, and forecasting. Show less

• 

  I1biometrics, Inc.

  Jan 2013 - Jan 2014

  Chief Financial Officer

  i1biometrics, Inc. is an early stage high technology company inventing and developing a sports medicine impact detection mouth guard, data collection, data retention, and data analysis system "on-line, in real time" designed to early detect both direct hit and circular impact damage to the brain. The system will be particularly useful in detecting second concussions occurring prior to the total healing of the first concussions. Second concussion damage is a leading cause of death in impact sports activities. The Company has recently completed a very successful beta site test during the Kansas/Missouri High School Football All-Star Game in Kansas City, Missouri this past Spring. All 90 participant football players were fitted with i1biometrics, Inc. mouth guards and the Company collected impact activity on all playing athletes (22 on the field at any given point in the game), retained the data for analysis, and linked the time line on the system to the simultaneous detailed video taping of the game. We expect additional beta site tests in the Spring of 2014 at major university Spring football programs followed by a late Spring 2014 roll-out to Revenue. Because of the wide press coverage of concussion damage from contact sport and the quality and proven functionality of our product and system, the future for i1biometrics, Inc. is deemed to be great.o Provided all financial management services at this start-up entity owned by a group of private equity firms. Show less

• 

  Pharmachem Laboratories, Inc.

  Jan 2014 - Jan 2015

  Corporate Controller

  Pharmachem's Corporate Headquarters is located in Kearny, New Jersey. Pharmachem is a $300 Million manufacturer of natural ingredients for the World manufacturing leaders in food, beverage, other consumer products, nutrition products, cosmetics, and fragrances in many plant facilities across the United States, Canada, and Mexico. Pharmachem Makes Ingredients Work™ - Pharmachem Laboratories, Inc.’s trademarked slogan tells much about what the Company does and is. Pharmachem is a premier international innovator, manufacturer and supplier of the finest quality ingredients. We deliver optimal solutions tailored to meet manufacturers’ needs across a complex matrix of industries including nutritionals, food and beverages, flavors and fragrance. From manufacturing standardized extracts and custom ingredients to developing original solutions for process problems, Pharmachem’s sophisticated technologies offer unique options for our customers. Extraordinary ingredients. Original solutions. Impeccable service … always at Pharmachem. Show less

• 

  Transdermal Specialties Global, Inc.

  Jan 2015 - now

  Chief Financial Officer

  Transdermal Specialties Global, Inc. is a start-up medical device entity developing the utilization of low cavitation ultrasound to deliver pharmaceutical compounds into the human body to enable the control of disease. The Company's U-Strip Active Transdermal Patch using the low cavitation ultrasound is designed to non-invasively deliver Eli Lilly and Company's Lispro 100 Insulin to Manage Type II Diabetes. The Company has completed fifteen Clinical Trials at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania including twelve patients wearing the patch for twenty-four hours to successfully deliver insulin lowering the patients' glucose level to near normal levels over a relatively short period of time, then maintaining the patients at the near normal glucose level. Transdermal Global is currently perfecting its device and preparing to seek permission from the U. S. Food and Drug Administration ("FDA") to perform its final Clinical Trial before receiving permission from the FDA to market its U-Strip Diabetes Control Management System to diabetes patients in the United States. A consortium of Investors from the Republic of Korea is providing the Company's current funding requirements, and may fund the Company's introduction of its technology to fight diabetes in China, Japan, and the Republic of Korea. Show less